Semaglutide vs Tirzepatide

Tirzepatide wins on raw weight loss. SURMOUNT-1 showed 20-22.5% average body weight loss over 72 weeks on the highest dose, compared to roughly 15% for semaglutide in STEP-1. That is a 5-7 percentage point gap, which on a 200-pound person is an extra 10-14 pounds. But individual response varies widely, and plenty of people do very well on semaglutide. The newer SELECT trial also showed semaglutide reduces cardiovascular events, which tirzepatide has not yet demonstrated.

Same active ingredient, different dose and delivery. Oral semaglutide needs a much higher daily dose to account for low oral bioavailability, so the pill version requires specific dosing rules (empty stomach, small sip of water, wait 30 minutes). Efficacy lands in a similar range to the injectable. Novo launched the oral direct-to-consumer at $149 per month in January 2026, which is roughly one-ninth the injectable list price. It is legitimate and FDA approved.

Tirzepatide, not semaglutide. In December 2024 the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, making it the first drug ever approved for that indication. That matters for insurance coverage - some plans that reject obesity-only claims will approve OSA claims, which opens a pathway tirzepatide users can exploit and semaglutide users cannot.

In August 2025 the FDA approved semaglutide for metabolic dysfunction-associated steatohepatitis (MASH), the modern name for non-alcoholic fatty liver disease with inflammation. It is a significant expansion because MASH affects an estimated 5% of US adults and has had almost no drug options. If you have a diagnosed fatty liver with elevated liver enzymes, semaglutide now has a specific on-label indication that tirzepatide does not.

Semaglutide works via GLP-1 receptor agonist that mimics incretin hormone to increase insulin secretion, slow. Tirzepatide works via Dual GIP/GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon, slows gastric. They differ in FDA approval status, efficacy data, and cost.

In clinical trials, Tirzepatide showed greater average weight loss (22.5%) compared to Semaglutide (15%). Individual results may vary.

Semaglutide typically costs $1,000 - $1,400/mo, while Tirzepatide costs $1,100 - $1,100/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.

Semaglutide is FDA-approved. Tirzepatide is FDA-approved. FDA approval indicates the treatment has met rigorous safety and efficacy standards.

Common side effects of Semaglutide include Nausea, Diarrhea, Vomiting. Common side effects of Tirzepatide include Nausea, Diarrhea, Decreased appetite. Always consult a healthcare provider about potential side effects.

Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.